$59.66
+0.23 (+0.39%)
Open$58.87
Previous Close$59.43
Day High$60.21
Day Low$58.31
52W High$72.36
52W Low$11.40
Volume—
Avg Volume534.6K
Market Cap1.67B
P/E Ratio—
EPS$-0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
-13.2% upside
Current
$59.66
$59.66
Target
$51.79
$51.79
$39.42
$51.79 avg
$66.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 244.72M | 82.73M | 183.45M |
| Net Income | -13,802,116 | -118,469,876 | 2.09M |
| Profit Margin | -5.6% | -151.2% | 1.1% |
| EBITDA | 50.54M | -141,571,926 | 3.06M |
| Free Cash Flow | — | — | 1.04M |
| Rev Growth | +183.6% | +13.1% | +5.3% |
| Debt/Equity | 7.43 | 4.99 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |